Cytospar
CytoSPAR: Rapid, sensitive biomolecular engineering & diagnostic testing with broad-spectrum recognition.
Founded
2011CytoSPAR: Rapid, sensitive biomolecular engineering & diagnostic testing with broad-spectrum recognition.
CytoSPAR, a biomolecular engineering and diagnostic testing company, was founded with the mission to revolutionize healthcare diagnostics through rapid, sensitive, and broad-spectrum recognition technologies. The company's core platform utilizes a cell-based targeting technique that delivers highly sensitive results in under 10 minutes. CytoSPAR's products focus on identifying a wide range of microbes, viruses, proteins, and antibodies, with a particular emphasis on personalized antibiotic treatment decisions through their innovative BLAST technology.
Notable achievements include the successful showcase of their BLAST technology at the ASM Microbe Conference in Atlanta, highlighting its capability for rapid phenotypic analysis in antibiotic susceptibility testing. This innovation allows for personalized antibiotic treatment decisions within hours rather than days, significantly impacting patient care and treatment outcomes. CytoSPAR's advancements in diagnostic testing are poised to transform healthcare by enabling faster and more accurate detection of pathogens and resistance profiles.
Companies similar to Cytospar include BioAmp diagnostics, Specific Diagnostics, Pattern Bioscience and Spectral Platforms.
Cytospar was founded in 2011.
Cytospar's headquarters is located in Plano, TX, US.
Cytospar's most recent funding round was for $2M (USD) in May 2022.
As of May 3, 2022, Cytospar has disclosed funding of $2M (USD). Undisclosed round amounts are excluded.
Cytospar has 5 employees as of Feb 5, 2024.
Spectral Platforms
